Abstract: A macrophage activator containing a Gc protein is provided by a simple process. The macrophage activator contains a Gc protein with no N-acetylgalactosamine attached thereto.

Abstract: An object of the present invention is to provide an enzyme-treated milk product, a method for preparing the same, a composition thereof comprising a pharmaceutical composition, and a product thereof comprising a pharmaceuticals. The enzyme-treated milk product can be obtained by a method for producing an enzyme-treated milk product including a step for bringing milk into contact with ?-galactosidase.

Abstract: Provided are inflammatory cytokine production inhibitors which inhibit the production of the inflammatory cytokines TNF-? and IL-1? and can be applied to drugs effective against inflammatory diseases caused by overproduction of these inflammatory cytokines, such as chronic inflammation (e.g., rheumatoid arthritis, ulcerative colitis) and Crohn's disease, as well as type 2 diabetes, depression, obesity, sepsis, atherosclerosis, dermatitis, dementia, schizophrenia, and Parkinson's disease, and also to foods and drinks such as health foods. The inflammatory cytokine production inhibitors contain as an active ingredient an enzyme-treated whey obtained by contacting whey with ?-galactosidase. The enzyme-treated whey is obtained by further contacting with sialidase.

Abstract: Inflammatory cytokine production inhibitors containing a tomato extract as an active ingredient, which inhibit the production of the inflammatory cytokines TNF-? and IL-6 and can be applied to drugs effective against inflammatory diseases caused by overproduction of these inflammatory cytokines, such as rheumatoid arthritis, ulcerative colitis, Crohn's disease, and type 2 diabetes, as well as to foods and drinks such as health foods, wherein the tomato extract is a raw tomato extract that is a high-molecular-weight fraction having a molecular weight of 10,000 or higher obtained by molecular weight fractionation.

Abstract: An object of the present invention is to provide a method of preparing an enzyme-treated bovine colostrum, comprising a step of bringing a bovine colostrum into contact with ?-galactosidase, and a pharmaceutical composition comprising the enzyme-treated bovine colostrum. The enzyme-treated bovine colostrum is useful for treatment, prevention, amelioration and maintenance of remission of diseases such as a cancer and an infectious disease.

Abstract: An object of the present invention is to provide an enzyme-treated milk product, a method for preparing the same, a composition thereof comprising a pharmaceutical composition, and a product thereof comprising a pharmaceuticals. The enzyme-treated milk product can be obtained by a method for producing an enzyme-treated milk product including a step for bringing milk into contact with ?-galactosidase.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: An object of the present invention is to provide a method of preparing an enzyme-treated bovine colostrum, comprising a step of bringing a bovine colostrum into contact with ?-galactosidase, and a pharmaceutical composition comprising the enzyme-treated bovine colostrum. The enzyme-treated bovine colostrum is useful for treatment, prevention, amelioration and maintenance of remission of diseases such as a cancer and an infectious disease.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: An engine includes an electric supercharger as a first supercharger, a turbocharger as a second supercharger, a secondary air supply passage, a secondary air valve and a catalyst. The electric supercharger is provided in an intake passage which is in communication with a combustion chamber, and supercharges intake air into the combustion chamber. The turbocharger is provided in the intake passage in series with respect to the electric supercharger, and supercharges intake air to the combustion chamber. The secondary air supply passage and the secondary air valve supply air compressed by the electric supercharger to a discharge passage which is in communication with the combustion chamber. The catalyst is provided in the discharge passage to purify exhaust gas.

Abstract: A test procedure control unit outputs control information including time setting information along a procedure for carrying out a transition test of a connection state of a mobile communication terminal (UE) of a cellular system. A transmitting/receiving unit transmits test signals corresponding to cells toward the UE in accordance with the control information, and receives a response signal from the UE. A reception measurement unit measures a transition time of the connection state among the cells of the UE, in accordance with the response signal. A deciding unit receives a measured result of the transition time, and decides whether or not the connection state of the UE is transiting in accordance with the scheduled time-passage. The indicating unit causes the display unit to indicate, the decided result transition among the cells in accordance with the time-passage, so as to be visually recognizable on a single coordinate.

Abstract: An engine includes an electric supercharger as a first supercharger, a turbocharger as a second supercharger, a secondary air supply passage, a secondary air valve and a catalyst. The electric supercharger is provided in an intake passage which is in communication with a combustion chamber, and supercharges intake air into the combustion chamber. The turbocharger is provided in the intake passage in series with respect to the electric supercharger, and supercharges intake air to the combustion chamber. The secondary air supply passage and the secondary air valve supply air compressed by the electric supercharger to a discharge passage which is in communication with the combustion chamber. The catalyst is provided in the discharge passage to purify exhaust gas.

Abstract: A test procedure control unit outputs control information including time setting information along a procedure for carrying out a transition test of a connection state of a mobile communication terminal (UE) of a cellular system. A transmitting/receiving unit transmits test signals corresponding to cells toward the UE in accordance with the control information, and receives a response signal from the UE. A reception measurement unit measures a transition time of the connection state among the cells of the UE, in accordance with the response signal. A deciding unit receives a measured result of the transition time, and decides whether or not the connection state of the UE is transiting in accordance with the scheduled time-passage. The indicating unit causes the display unit to indicate, the decided result transition among the cells in accordance with the time-passage, so as to be visually recognizable on a single coordinate.

Abstract: A startup control apparatus of an internal combustion engine is provided wherein when an engine starting capability determining device determines that the engine can be successfully started even if driving of part of the fuel injector valves is stopped during engine startup, the fuel injection is stopped with respect to the part of the fuel injector valves. With this arrangement, overshoot of the engine speed that would otherwise occur upon the start of the engine can be suppressed, and unburned fuel components can be prevented from being discharged, thus assuring improved exhaust gas characteristics and improved fuel efficiency.